Share Issue/Capital Change • Jun 29, 2020
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 4175R
Diaceutics PLC
29 June 2020
29 June 2020
Diaceutics PLC
("Diaceutics" or the "Company")
Results of General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that, further to the Company's announcement on 11 June 2020, and in connection with the Placing of 14,371,931 new ordinary shares in the Company at a price of 145p per share (comprising a Firm Placing of 10,437,000 new ordinary shares and a Conditional Placing of 3,700,931 new ordinary shares), all resolutions put to shareholders at the general meeting held by the Company earlier today were duly passed unanimously.
10,437,000 new ordinary shares in the Company, the subject of the Firm Placing, were admitted to trading on AIM on 16 June 2020. Application has been made for the admission of 3,700,931 new ordinary shares in the Company, to trading on AIM, which is expected on 30 June 2020.
For the purpose of the Disclosure and Transparency Rules, following the issue of the 3,700,931 Conditional Placing shares in connection with the Conditional Placing approved today, on 30 June 2020 the Company's issued share capital admitted to trading on AIM will comprise 84,068,923 ordinary shares of 0.2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:
| Resolution | For & Discretionary |
Against | Withheld | Total votes cast | |||
| Number of votes | % | Number of votes | % | Number of votes | |||
| 1 | Ordinary resolution to authorise the directors to allot shares | 61,914,093 | 100.00% | 1,084 | 0.00% | - | 69,915,177 |
| 2 | Special resolution to authorise the directors to disapply pre-emption rights | 61,875,724 | 99.94% | 39,453 | 0.06% | - | 69,915,177 |
| Enquiries Diaceutics PLC |
|
| Stuart Hunt, Head of Investor Relations | Tel: +44 (0)7815 778 536 |
| Cenkos Securities PLC (Nomad & Broker) | Tel: +44(0)20 7397 8900 |
| Callum Davidson / Giles Balleny | |
| Michael Johnson (Sales) | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Anna Dunphy | Tel: +44 (0)7876 741 001 |
| Paul McManus | Tel: +44 (0)7980 541 893 |
About Diaceutics
Diaceutics PLC is a diagnostic commercialisation company for the Precision Medicine industry. The Company, quoted on the AIM Market of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
ROMEADKNASLEEFA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.